The case for a global therapeutics development coalition: Building a therapeutics pipeline for pandemic and endemic diseases
PLOS Glob Public Health
.
2024 Aug 30;4(8):e0003654.
doi: 10.1371/journal.pgph.0003654.
eCollection 2024.
Authors
Shingai Machingaidze
1
,
Carmen Pérez Casas
2
,
Sheila Mburu
1
,
Ruxandra Draghia-Akli
3
,
Charles Mowbray
4
,
James Rosen
5
,
Esteban Burrone
6
,
Mona Nemer
7
,
Victor Dzau
8
Affiliations
1
International Pandemic Preparedness Secretariat (IPPS), London, United Kingdom.
2
Unitaid, Geneva, Switzerland.
3
International Readiness for Preventing Infectious Viral Disease (INTREPID Alliance), Cambridge, Massachusetts, United States of America.
4
Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland.
5
Rapidly Emerging Antiviral Drug Development Initiative (READDI), Chapel Hill, North Carolina, United States of America.
6
Medicines Patent Pool (MPP), Geneva, Switzerland.
7
Office of the Chief Science Advisor, Government of Canada, Ottawa, Canada.
8
National Academy of Medicine, Washington DC, United States of America.
PMID:
39213286
PMCID:
PMC11364229
DOI:
10.1371/journal.pgph.0003654
No abstract available
Grants and funding
The authors received no specific funding for this work.